Objection: The purpose of this work was to discuss the effects and relative mechanisms of F11-AS1 in cervical cancer treatment by vitro study. Methods: 20 pairs of cervical carcinoma and adjacent normal tissue were collected and measured pathology and F11-AS1 expression by HE and HIS staining. Measuring F11-AS1 expression in difference cell lines and cell groups by RT-qPCR assay. Transfection F11-AS1 in Hela cells, evaluating hela cell biological including proliferation, apoptosis, invasion and migration by MTT, flow cytometry, transwell and wound healing assay. PTEN, p-PI3K and AKT proteins expression were evaluated by WB assay, and p-PI3K nuclear volume were measured by cellular immunofluorescence assay. Results: F11-AS1 level of cancer tissues were significantly down-regulation with state increasing by ISH assay (P < 0001, respectively). After transfection with F11-AS1, the Hela cell proliferation rate was significantly down-regulation with apoptosis significantly increasing (P < 0005); The invasion Hela cell number and wound healing rate were significantly depressed with F11-AS1 transfection (P < 0005). By WB assay, PTEN protein expression was significantly increasing, and p-PI3K and AKT proteins expression were significantly inhibited (P < 0005). By cellular immunofluorescence assay, p-PI3K nuclear volume of pcDNA3.1/F11-AS1 group was significantly depressed (P < 0005). Conclusion: lncRNA F11-AS1 suppressed cervical cancer biological activities by regulation PTEN/p-PI3K/AKT pathway in vitro study.